{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:17:26Z","timestamp":1790695046895,"version":"4.1.0"},"reference-count":46,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Henan Province Medical Science and Technology Research plan joint construction project","award":["SBGJ202102011"],"award-info":[{"award-number":["SBGJ202102011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cardiovascular disease is a major cause of increasing morbidity and mortality in type 1 diabetes mellitus (T1DM). Although insulin therapy is the cornerstone of T1DM, its difficult use and narrow therapeutic index make it difficult for patients to reach glycated hemoglobin targets, increasing the risk of cardiovascular events. Therefore, the combination of sodium-glucose transporter 2 inhibitors (SGLT2i) can likely improve or provide more cardiovascular benefits to patients with T1DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study conducted a systematic review and meta-analysis of randomized controlled trials published in PubMed, Scopus, Cochrane Library, Web of Science, and Embase up to June 30, 2024. The data from eligible trials were summarized as mean difference (MD) and SD for continuous methods and 95% CI and risk ratio (RR) for dichotomous approaches.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 16 articles that met the inclusion criteria. Compared with placebo, SGLT2i significantly reduced glycated hemoglobin levels (MD: \u22120.40%, 95% CI, \u22120.44 to \u22120.36; P &amp;lt; .00001, I2 = 37%), and body weight (MD: \u22123.31\u2005kg, 95% CI, \u22123.67\u2005to \u22122.96; P &amp;lt; .00001, I2 = 70%) in insulin-using patients with T1DM, and did not significantly increase the risk of hypoglycemia and severe hypoglycemia. It should be noted that SGLT2i significantly increased the risk of diabetic ketoacidosis acidosis (RR: 4.45, 95% CI, 2.81-7.05, P &amp;lt; .00001, I2 = 0%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SGLT2i not only significantly improved glycated hemoglobin and body weight in patients with T1DM but also significantly increased the risk of diabetic ketoacidosis acidosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf016","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T11:37:06Z","timestamp":1736941026000},"page":"2071-2081","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1210","volume":"110","author":[{"given":"Songwei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiac Intensive Care Unit, People's Hospital of Zhengzhou University (Henan Provincial People's Hospital) , Zhengzhou, Henan 450003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei 430030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abudunaibi","family":"Balati","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei 430030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5110-5819","authenticated-orcid":false,"given":"Bing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Practice, People's Hospital of Zhengzhou University (Henan Provincial People's Hospital) , Zhengzhou, Henan 450003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4469-7386","authenticated-orcid":false,"given":"Lei","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei 430030 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-003X","authenticated-orcid":false,"given":"Dan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiac Intensive Care Unit, People's Hospital of Zhengzhou University (Henan Provincial People's Hospital) , Zhengzhou, Henan 450003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"6","key":"2025062422083707200_dgaf016-B1","doi-asserted-by":"crossref","first-page":"14791641231221763","DOI":"10.1177\/14791641231221763","article-title":"Type 1 diabetes mellitus disease burden in high health expenditure countries between 1990 and 2019","volume":"20","author":"Edwards","year":"2023","journal-title":"Diab Vasc Dis Res"},{"issue":"11","key":"2025062422083707200_dgaf016-B2","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"2025062422083707200_dgaf016-B3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up","volume":"39","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"2025062422083707200_dgaf016-B4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care"},{"key":"2025062422083707200_dgaf016-B5","doi-asserted-by":"crossref","first-page":"e075681","DOI":"10.1136\/bmj-2023-075681","article-title":"New advances in type 1 diabetes","volume":"384","author":"Subramanian","year":"2024","journal-title":"BMJ"},{"issue":"10","key":"2025062422083707200_dgaf016-B6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"2025062422083707200_dgaf016-B7","doi-asserted-by":"crossref","first-page":"44128","DOI":"10.1038\/srep44128","article-title":"The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"2025062422083707200_dgaf016-B8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025062422083707200_dgaf016-B9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/dom.14248","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies","volume":"23","author":"Phillip","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2025062422083707200_dgaf016-B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.24920\/J1001-9242.2007.003","article-title":"Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"32","author":"Yang","year":"2017","journal-title":"Chin Med Sci J"},{"issue":"4","key":"2025062422083707200_dgaf016-B11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3892\/etm.2021.9813","article-title":"Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"21","author":"Huang","year":"2021","journal-title":"Exp Ther Med"},{"key":"2025062422083707200_dgaf016-B12","doi-asserted-by":"crossref","first-page":"20420188231180987","DOI":"10.1177\/20420188231180987","article-title":"Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment","volume":"14","author":"Edwards","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2025062422083707200_dgaf016-B13","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"issue":"3","key":"2025062422083707200_dgaf016-B14","doi-asserted-by":"crossref","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","article-title":"Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"9","author":"Arnott","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025062422083707200_dgaf016-B15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"2025062422083707200_dgaf016-B16","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane database Syst Rev"},{"issue":"11","key":"2025062422083707200_dgaf016-B17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"1","key":"2025062422083707200_dgaf016-B18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-psych-010418-102803","article-title":"How to do a systematic review: a best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses","volume":"70","author":"Siddaway","year":"2019","journal-title":"Annu Rev Psychol"},{"issue":"11","key":"2025062422083707200_dgaf016-B19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2025062422083707200_dgaf016-B20","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"2025062422083707200_dgaf016-B21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"2025062422083707200_dgaf016-B22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2025062422083707200_dgaf016-B23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/dom.14362","article-title":"Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: subgroup analysis of the DEPICT-2 study","volume":"23","author":"Araki","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2025062422083707200_dgaf016-B24","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"2025062422083707200_dgaf016-B25","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"Hba1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"2025062422083707200_dgaf016-B26","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/dom.14271","article-title":"Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT) 1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index \u2265 27\u2005kg\/m2","volume":"23","author":"Danne","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"2025062422083707200_dgaf016-B27","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2025062422083707200_dgaf016-B28","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/dom.13825","article-title":"Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: the inTandem4 trial","volume":"21","author":"Baker","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2025062422083707200_dgaf016-B29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2025062422083707200_dgaf016-B30","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"2025062422083707200_dgaf016-B31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"2025062422083707200_dgaf016-B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/dia.2020.0079","article-title":"Effects of sotagliflozin combined with intensive insulin therapy in young adults with poorly controlled type 1 diabetes: the JDRF sotagliflozin study","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"2025062422083707200_dgaf016-B33","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"2025062422083707200_dgaf016-B34","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/dom.13807","article-title":"Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial","volume":"21","author":"Kaku","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2025062422083707200_dgaf016-B35","doi-asserted-by":"crossref","unstructured":"Wang S, Zhang Y, Balati A, Li B, Dai L, Yu D. Supplementary Material and Data for \u201cEffect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomised Controlled Trials\u201d [Data set]. Zenodo. 2025. 10.5281\/zenodo.14748547","DOI":"10.1210\/clinem\/dgaf016"},{"key":"2025062422083707200_dgaf016-B36","doi-asserted-by":"crossref","first-page":"117158","DOI":"10.1016\/j.atherosclerosis.2023.06.005","article-title":"Cardiovascular disease in type 1 diabetes, an underestimated danger: epidemiological and pathophysiological data","volume":"394","author":"Verg\u00e8s","year":"2024","journal-title":"Atherosclerosis"},{"issue":"5","key":"2025062422083707200_dgaf016-B37","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.2337\/db15-1517","article-title":"Risk factors for cardiovascular disease in type 1 diabetes","volume":"65","author":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Research Group","year":"2016","journal-title":"Diabetes"},{"issue":"4","key":"2025062422083707200_dgaf016-B38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc19-2292","article-title":"Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT\/EDIC study","volume":"43","author":"Bebu","year":"2020","journal-title":"Diabetes Care"},{"issue":"22","key":"2025062422083707200_dgaf016-B39","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.jacc.2021.03.335","article-title":"Glycated hemoglobin and subclinical atherosclerosis in people without diabetes","volume":"77","author":"Rossello","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2025062422083707200_dgaf016-B40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.diabet.2020.09.001","article-title":"Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms","volume":"46","author":"Verg\u00e8s","year":"2020","journal-title":"Diabetes Metab"},{"issue":"1","key":"2025062422083707200_dgaf016-B41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/XCE.0000000000000167","article-title":"Cardiovascular disease in type 1 diabetes","volume":"8","author":"Sharma","year":"2019","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"3","key":"2025062422083707200_dgaf016-B42","doi-asserted-by":"crossref","first-page":"e00129","DOI":"10.1002\/edm2.129","article-title":"Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes","volume":"3","author":"Schnell","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"9896","key":"2025062422083707200_dgaf016-B43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"2025062422083707200_dgaf016-B44","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025062422083707200_dgaf016-B45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2025062422083707200_dgaf016-B46","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf016\/61440279\/dgaf016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/7\/2071\/61440279\/dgaf016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/7\/2071\/61440279\/dgaf016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:08:51Z","timestamp":1750817331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/7\/2071\/7954283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf016","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,1,15]]}}}